Here’s what you need to know about the Consumer Eagle report.
1. Only seven analysts currently cover AmSurg. Of the seven, five rate it a buy, two a hold and zero rated it as a sell. The highest target is $97 while $84 is the lowest. The $91 average target in their analysis is 39.7 percent above the current $65.11 trading price.
2. AmSurg’s institutional sentiment decreased to $0.86 in the second quarter from $0.99 it was at in the first quarter.
The ratio dropped because 29 funds sold all AmSurg shares while 118 reduced their positions. Thirty-nine funds did buy AmSurg and 88 increased their positions. Funds own 52.50 million shares, which is down from 55.5 million in the first quarter.
3. AmSurg stock has declined 8.8 percent since January 26, 2016. It has underperformed the S&P 500 by 23.33 percent.
More transactions/valuations news:
5 reasons why Tenet’s stock is falling after 5th quarter of net losses
Striking when the market is hot: Industry experts on when to sell your ASC
Tenet shares jump 3.32% — 5 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.